Autopsy report · NCT01674010
Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder
Cause of deathFunding or business
“Business Decision”
Life of this trial
- Ran for about 1 year 10 months before it stopped.
- 309 participants enrolled.
- Results were posted on the registry 1 year 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- OPKO Health, Inc.
- Sponsor type
- Industry
- Conditions
- Bipolar 1 Disorder
- Interventions
- ELND005; Lamotrigine; Valproic acid; Placebo
- Participants
- 309
- Sites
- 82
- Countries
- Bulgaria, Canada, Czechia, France, Poland, Romania, Spain, Turkey (Türkiye), United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.